on September 1, 2005
Published online before print September 1, 2005, doi: 10.1161/01.ATV.0000184779.01822.9d
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on July 26, 2005
Accepted on August 19, 2005
Single Perivascular Delivery of Mitomycin C Stimulates p21 Expression and Inhibits Neointima Formation in Rat Arteries
Juan F. Granada ;
From The Methodist Research Institute (J.F.G., G.L.K., A.E.R.), Houston, Tex; Michael E. DeBakey VA Medical Center (D.E., A.N.K.X.L., K.J.P., H.W., W.D.) and the Departments of Medicine (M.A.A.) and Pharmacology (W.D.), Baylor College of Medicine, Houston, Tex.
* To whom correspondence should be addressed. E-mail: wdurante{at}bcm.tmc.edu.
Objective--Mitomycin C (MMc) is an antibiotic that exerts a potent antiproliferative effect in tumor cells. Because the proliferation of vascular smooth muscle cells (VSMCs) plays a prominent role in the development of restenosis after percutaneous coronary interventions, the present study examined the effect of MMc on VSMC proliferation and on neointima formation after arterial balloon injury.
Methods and Results--Treatment of cultured rat aortic VSMCs with MMc (1 nmol to 30 µmol/L) inhibited smooth muscle cell (SMC) proliferation in a concentration-dependent manner. Whereas high concentrations of MMc (1 to 30 µmol/L) induced SMC apoptosis, as reflected by DNA laddering and caspase-3 activation, lower concentrations of MMc (1 to 300 nmol) directly inhibited SMC growth by arresting cells in the G2/M phase of the cell cycle. The antiproliferative action of MMc was associated with a selective increase in the expression of the cyclin-dependent kinase inhibitor p21, and with a decrease in cyclin B1-cyclin-dependent kinase-1 complex activity. Finally, the local perivascular delivery of MMc immediately after balloon injury of rat carotid arteries induced p21 expression and markedly attenuated neointima formation.
Conclusion--These studies demonstrate that MMc exerts a potent inhibitory effect on VSMC proliferation and neointima formation after arterial injury. MMc represents a potentially new therapeutic agent in treating and preventing vasculoproliferative disease.
Key words: angioplasty • arteries • mitomycin C • restenosis • smooth muscle cells
This article has been cited by other articles:
 |
|
 |
|
  K. J. Peyton, D. Ensenat, M. A. Azam, A. N. Keswani, S. Kannan, X.-m. Liu, H. Wang, D. A. Tulis, and W. Durante Arginase Promotes Neointima Formation in Rat Injured Carotid Arteries Arterioscler Thromb Vasc Biol, April 1, 2009; 29(4): 488 - 494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X.-m. Liu, M. A. Azam, K. J. Peyton, D. Ensenat, A. N. Keswani, H. Wang, and W. Durante Butylated hydroxyanisole stimulates heme oxygenase-1 gene expression and inhibits neointima formation in rat arteries Cardiovasc Res, April 1, 2007; 74(1): 169 - 179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-L. Wang, J.-F. Han, X.-Y. He, X.-R. Wang, and J.-Y. Hong Genetic Variation of Human Cytochrome P450 Reductase as a Potential Biomarker for Mitomycin C-Induced Cytotoxicity Drug Metab. Dispos., January 1, 2007; 35(1): 176 - 179. [Abstract] [Full Text] [PDF]
|
|